← 返回

高 TRGV 9 亚家族表达标志着急性髓系白血病患者总生存期的改善

英文原题:High TRGV 9 Subfamily Expression Marks an Improved Overall Survival in Patients With Acute Myeloid Leukemia.

查看英文原题

High TRGV 9 Subfamily Expression Marks an Improved Overall Survival in Patients With Acute Myeloid Leukemia.

PubMed 2022/02/10(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

TRGV 使用的限制可能与γδ T 细胞的使用偏好有关。TRGV 亚家族的高表达可能与 AML 中更好的 OS 相关。较高的 TRGV 9 表达和增加的 Vγ9 + Vδ2 + T 细胞亚家族可能表明 AML 患者有更好的预后。

研究思路结论见上方概要

急性髓系白血病(AML)中异质性T细胞具有由不同T细胞受体(TCR)产生的组合多样性。γδ T细胞是T细胞的一个独特亚群,包含TCRγ(TRGV)和TCRδ(TRDV)亚家族,具有多样的结构和功能异质性。我们之前的研究表明,克隆扩增的TRDV T细胞可能有利于针对AML的免疫应答。然而,AML中TRGV库的特征仍不清楚。为了全面表征γδ T细胞的特征,我们分析了TRGV I-III亚家族(TRGV II也称为TRVG 9)的分布和克隆性、γδ T细胞亚群的比例及其对AML患者总生存期(OS)的影响。

本研究通过Genescan分析检测了初诊AML患者外周血γδ T细胞中TRGV亚家族互补决定区3(CDR3)的长度。采用实时定量PCR检测TRGV亚家族的表达水平。通过多色流式细胞术检测总γδ T细胞及其Vγ9+Vδ2+T细胞亚群的比例。我们进一步比较了TRGV基因表达水平、Vγ9+Vδ2+T细胞比例与OS之间的相关性。

我们首次发现TRGV亚家族的分布模式和克隆性发生了改变。AML样本中三个TRGV亚家族的表达频率和基因表达水平显著低于健康个体(HIs)。与HIs相比,AML患者中总γδ T细胞和Vγ9 + Vδ2 + T细胞的比例也显著降低。此外,TRGV基因表达水平较高且Vγ9 + Vδ2 + T细胞比例较高的AML患者,其OS优于对照组。进一步研究发现,TRGV 9高表达和Vγ9 + Vδ2 + T细胞比例高被确定为AML患者完全缓解的独立保护因素。

展开英文摘要原文

Heterogeneous T cells in acute myeloid leukemia (AML) have the combinatorial variety generated by different T cell receptors (TCRs). γδ T cells are a distinct subgroup of T cells containing TCRγ ( TRGV ) and TCRδ ( TRDV ) subfamilies with diverse structural and functional heterogeneity. Our previous study showed that clonally expanded TRDV T cells might benefit the immune response directed against AML. However, the features of the TRGV repertoire in AML remain unknown. To fully characterize the features of γδ T cells, we analyzed the distribution and clonality of TRGV I-III subfamilies ( TRGV II is also termed TRVG 9 ), the proportions of γδ T cell subsets, and their effects on the overall survival (OS) of patients with AML.

In this study, the complementarity-determining region 3 (CDR3) size of TRGV subfamilies in γδ T cells of peripheral blood (PB) from de novo AML patients were analyzed by Genescan analysis. Expression levels of TRGV subfamilies were performed by real-time quantitative PCR. The proportions of total γδ T cells and their Vγ9 + Vδ2 + T cells subsets were detected by multicolor flow cytometry assay. We further compared the correlation among the TRGV gene expression levels, the proportion of Vγ9 + Vδ2 + T cells, and OS in AML.

We first found that the distribution pattern and clonality of TRGV subfamilies were changed. The expression frequencies and gene expression levels of three TRGV subfamilies in AML samples were significantly lower than those in healthy individuals (HIs). Compared with HIs, the proportions of total γδ T cells and Vγ9 + Vδ2 + T cells were also significantly decreased in patients with AML. In addition, patients with AML who had higher expression levels of the TRGV gene and higher proportion of Vγ9 + Vδ2 + T cells showed better OS than their counterparts. Furthermore, high expression levels of TRGV 9 and proportion of Vγ9 + Vδ2 + T cells were identified as independent protective factors for complete remission in patients with AML.

The restriction of TRGV usage might be related to the preference of usage of γδ T cells. Higher expression of TRGV subfamilies might be associated with better OS in AML. Higher TRGV 9 expression and increased Vγ9 + Vδ2 + T cells subfamilies might indicate a better prognosis in patients with AML.

论文信息

作者
Kong X、Zheng J、Liu X、Wang W、Jiang X、Chen J、Lai J、Jin Z
单位
Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.China
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 35222403 · DOI 10.3389/fimmu.2022.823352